Look Beyond Biopharmaceutical Industry Hype - Exubera and Cimzia provide a warning to CMOs that clinical and commercial success aren't guaranteed - BioPharm International


Look Beyond Biopharmaceutical Industry Hype
Exubera and Cimzia provide a warning to CMOs that clinical and commercial success aren't guaranteed

BioPharm International
Volume 21, Issue 1

Another case in point occurred this past November, when the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on UCB's Cimzia as a treatment for Crohn's disease. The CHMP's opinion, which UCB plans to appeal, cited issues relating to clinical efficacy, risk of bleeding, and quality control in manufacture of the active ingredient. Crohn's is one of only several indications for which UCB is targeting Cimzia, with rheumatoid arthritis being the biggest opportunity. While the clinical efficacy issues are specific to Crohn's, the bleeding and quality control issues could have broader implications for other indications.

The CHMP's opinion could have a big impact on Lonza, which signed a six-year agreement with UCB in 2005 to supply the API for Cimzia, a PEGylated antibody fragment. Under the agreement, Lonza is to dedicate to UCB half of the capacity of two 15,000-L microbial fermentation bioreactors it has built at its site in Visp, Switzerland, at a cost of $165 million. Lonza is one of the industry's savviest players and its contract probably has provisions that will protect at least some of its downside risk. However, the uncertainty factor will probably weigh on the company for some time and make it difficult to arrange for alternate uses of the capacity. (Lonza has not issued a statement on the Cimzia situation yet.)

The Committee for Medicinal Products for Human Use's decision shocked UCB and the biopharmaceutical industry, which has viewed Cimzia's approval and market success as an almost foregone conclusion for several years. Not only did that perception jump the gun on regulatory approval, it also overlooked the fact that Cimzia would be a late arrival in the anti-TNF market, where existing candidates including Amgen's Enbrel, J&J's Remicade, and Abbott's Humira are duking it out and expanding their indications across the autoimmune disease spectrum.

The reality of the contract manufacturing business model is that it shares a major characteristic of the proprietary product model: CMOs must constantly renew their product portfolio, replacing late lifecycle products whose sales are declining with new products that can be expected to grow. The odds are against the success of those new products, however, most of which are signed up when they are still in clinical trials and have yet to gain regulatory approval, let alone commercial sales. In an increasingly hostile regulatory and commercial environment, the continued success of contract manufacturing organizations will require that they look beyond the biopharmaceutical industry hype and take careful measure of their clients' prospects for success.

Jim Miller is president of PharmSource Information Services Inc. , Springfield, VA, 703.383.4903,

blog comments powered by Disqus



First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here